Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25702091
DOI
10.1007/s13277-015-3249-x
PII: 10.1007/s13277-015-3249-x
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom farmakoterapie genetika patologie MeSH
- chinazoliny aplikace a dávkování MeSH
- erbB receptory antagonisté a inhibitory genetika MeSH
- erlotinib MeSH
- gefitinib MeSH
- inhibitory proteinkinas aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nemalobuněčný karcinom plic farmakoterapie genetika patologie MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- protoonkogenní proteiny p21(ras) MeSH
- protoonkogenní proteiny genetika MeSH
- Ras proteiny genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- statiny aplikace a dávkování MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- chinazoliny MeSH
- EGFR protein, human MeSH Prohlížeč
- erbB receptory MeSH
- erlotinib MeSH
- gefitinib MeSH
- inhibitory proteinkinas MeSH
- KRAS protein, human MeSH Prohlížeč
- protoonkogenní proteiny p21(ras) MeSH
- protoonkogenní proteiny MeSH
- Ras proteiny MeSH
- statiny MeSH
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumour cell growth, invasion and metastatic potential. We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. Twelve patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of patients' survival (progression-free survival (PFS) and overall survival (OS)) according to the treatment used was performed using the Gehan-Wilcoxon test. The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (p = 0.025, p = 0.130). In conclusion, the study results suggest significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, and the difference in OS was not significant.
Zobrazit více v PubMed
Nature. 1990 Feb 1;343(6257):425-30 PubMed
Curr Opin Oncol. 2001 Nov;13(6):491-8 PubMed
J Thorac Oncol. 2010 Aug;5(8):1175-84 PubMed
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 PubMed
Anticancer Res. 2010 Dec;30(12):5121-8 PubMed
Clin Cancer Res. 2011 Mar 15;17(6):1553-60 PubMed
Clin Cancer Res. 1996 Mar;2(3):483-91 PubMed
Cancer Genet. 2013 Jan-Feb;206(1-2):26-31 PubMed
Invest New Drugs. 2010 Dec;28(6):791-9 PubMed
Cancer Lett. 2001 Sep 28;171(1):1-10 PubMed
Neoplasia. 2009 Oct;11(10):1084-92 PubMed
Neoplasma. 2013;60(1):26-32 PubMed
Eur Respir J. 2001 Dec;18(6):1059-68 PubMed
Cell Death Dis. 2013 Sep 26;4:e814 PubMed
J Clin Oncol. 2005 Sep 1;23(25):5900-9 PubMed
Nature. 2008 Oct 23;455(7216):1069-75 PubMed
J Thorac Oncol. 2006 Jan;1(1):7-9 PubMed
Curr Opin Investig Drugs. 2009 Dec;10 (12 ):1305-14 PubMed
Lancet Oncol. 2001 Sep;2(9):533-43 PubMed
Ann Surg Oncol. 2010 Apr;17 (4):1168-76 PubMed
Cancer Res. 1991 Jul 1;51(13):3602-9 PubMed
Clin Cancer Res. 2003 Jan;9(1):10-9 PubMed
Nat Rev Cancer. 2003 Jun;3(6):459-65 PubMed
J Clin Oncol. 2002 Jan 1;20(1):110-24 PubMed
Leukemia. 2002 Apr;16(4):508-19 PubMed
